DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel
Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)

Date: September 23, 2021

Time: 1:00 PM to 3:30 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Ipolia R. Ramadan, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 827-4471
ramadanir@mail.nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs,
National Institutes of Health, HHS)

Dated: July 30, 2021.

Miguelina Perez,
Program Analyst,

Office of Federal Advisory Committee Policy.

[FR Doc. 2021-16608 Filed: 8/3/2021 8:45 am; Publication Date: 8/4/2021]